CD4 and neoplasm: Meanwhile, blockade of the TGF-βR axis using the specific inhibitors could largely protect CD8+ and CD4+ ROR1-CAR-T cells from the suppressive impacts of TGF-β, facilitating their tumor-suppressive activity in the 3D tumor model [29].